Nanocarriers for Fibrosis Resolution: Targeting Hepatic Stellate Cells in Fatty Liver Disease

<p> Introduction: As a vital organ in the human body, the liver plays a crucial role in physiological functions, including regulating red blood cell storage and breakdown, detoxification, and the synthesis of hormones and plasma proteins. This article provides a concise overview of fatty liver disease, highlighting its connection to liver fibrosis and the role of hepatic stellate cells. It also focuses on nanotechnology-based therapeutic approaches for liver fibrosis. </p><p> Methodology: To analyze the mechanisms, the role of hepatic stellate cells, and targeted pre-clinical studies on the reversal of liver fibrosis in fatty liver disease, a literature review was conducted using databases such as PubMed, ScienceDirect, and the Wiley Online Library. </p><p> Results: Fatty liver disease is one of the most common complications of chronic liver conditions. Hepatic stellate cells are key contributors to hepatic fibrosis, leading to persistent liver damage. Emerging nanotechnologies, including liposomes, niosomes, nanoemulsions, and polymeric nanoparticles, have shown potential in pre-clinical models for resolving liver fibrosis and improving liver health. </p><p> Discussion: Findings suggest that nanotechnology-enabled drug delivery systems offer a promising approach by specifically targeting hepatic stellate cells and mitigating liver fibrosis. However, further research is needed to overcome limitations associated with nanocarriers and to address gaps in clinical translation. </p><p> Conclusion: The findings support ongoing research into emerging therapeutics, including nanotechnology, as a vital strategy for managing chronic liver conditions and improving patient outcomes. </p>